Fennec Pharmaceuticals Inc.

NasdaqCM FENC

Fennec Pharmaceuticals Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -8.04

Fennec Pharmaceuticals Inc. Debt to Equity Ratio is -8.04 for the Trailing 12 Months (TTM) ending September 30, 2024. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqCM: FENC

Fennec Pharmaceuticals Inc.

CEO	Mr. Rostislav Raykov
IPO Date	Sept. 15, 2017
Location	United States
Headquarters	68 TW Alexander Drive
Employees	29
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Key trends

Past 5 years